Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Voyager Therapeutics Inc's Business Segments
Voyager Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Single reportable segment
Total Revenue
$ 3
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Single reportable segment100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single reportable segment | $ 3 | 100% |
Description of Voyager Therapeutics Inc
Voyager Therapeutics Inc is a clinical-stage gene therapy company that is focused on developing life-changing treatments for patients suffering from severe neurological diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Voyager Therapeutics utilizes adeno-associated viral (AAV) vector technology to deliver gene therapies directly into the central nervous system (CNS). Their approach involves using AAV vectors to introduce therapeutic genes into targeted areas of the CNS to restore function and potentially cure these debilitating diseases.
The company's pipeline consists of multiple programs targeting different neurological disorders. Their most advanced program, VY-AADC, is being developed for the treatment of Parkinson's disease. VY-AADC is designed to deliver the AADC gene into the putamen region of the brain, which produces the enzyme necessary for converting levodopa into dopamine. By increasing the production of dopamine, VY-AADC aims to improve motor function in Parkinson's patients.
Voyager Therapeutics is also actively developing gene therapies for other CNS disorders, including Huntington's disease, amyotrophic lateral sclerosis (ALS), and Friedreich's ataxia. These programs are in various stages of preclinical and early-stage clinical development.
In addition to their proprietary gene therapy platform, Voyager Therapeutics has formed strategic collaborations with other pharmaceutical companies, such as AbbVie and Neurocrine Biosciences, to jointly develop and commercialize gene therapies for specific indications.
The company has a team of experienced scientists, researchers, and clinicians who are pioneers in the field of gene therapy. They have expertise in vector design, gene delivery, and therapeutic gene development. Voyager Therapeutics also possesses a robust intellectual property portfolio to protect their technologies and potential products.
Voyager Therapeutics is committed to conducting rigorous clinical trials to assess the safety and efficacy of their gene therapies. Their approach involves close collaborations with regulatory authorities, patient advocacy groups, and healthcare providers to ensure the successful development and future commercialization of their treatments.
Overall, Voyager Therapeutics Inc is at the forefront of using gene therapy to address severe neurological disorders. Their innovative approach, strategic partnerships, and dedicated team position them well to make a significant impact in improving the lives of patients suffering from these devastating diseases.
Voyager Therapeutics utilizes adeno-associated viral (AAV) vector technology to deliver gene therapies directly into the central nervous system (CNS). Their approach involves using AAV vectors to introduce therapeutic genes into targeted areas of the CNS to restore function and potentially cure these debilitating diseases.
The company's pipeline consists of multiple programs targeting different neurological disorders. Their most advanced program, VY-AADC, is being developed for the treatment of Parkinson's disease. VY-AADC is designed to deliver the AADC gene into the putamen region of the brain, which produces the enzyme necessary for converting levodopa into dopamine. By increasing the production of dopamine, VY-AADC aims to improve motor function in Parkinson's patients.
Voyager Therapeutics is also actively developing gene therapies for other CNS disorders, including Huntington's disease, amyotrophic lateral sclerosis (ALS), and Friedreich's ataxia. These programs are in various stages of preclinical and early-stage clinical development.
In addition to their proprietary gene therapy platform, Voyager Therapeutics has formed strategic collaborations with other pharmaceutical companies, such as AbbVie and Neurocrine Biosciences, to jointly develop and commercialize gene therapies for specific indications.
The company has a team of experienced scientists, researchers, and clinicians who are pioneers in the field of gene therapy. They have expertise in vector design, gene delivery, and therapeutic gene development. Voyager Therapeutics also possesses a robust intellectual property portfolio to protect their technologies and potential products.
Voyager Therapeutics is committed to conducting rigorous clinical trials to assess the safety and efficacy of their gene therapies. Their approach involves close collaborations with regulatory authorities, patient advocacy groups, and healthcare providers to ensure the successful development and future commercialization of their treatments.
Overall, Voyager Therapeutics Inc is at the forefront of using gene therapy to address severe neurological disorders. Their innovative approach, strategic partnerships, and dedicated team position them well to make a significant impact in improving the lives of patients suffering from these devastating diseases.
Voyager Therapeutics Inc. is a pioneering clinical-stage gene therapy company focused on developing innovative treatments primarily for severe neurological diseases. Through its advanced gene therapy approaches, Voyager aims to deliver transformative life-changing therapies and long-lasting benefits to patients suffering from debilitating conditions. The company operates in the intersection of biotechnology and gene therapy, pursuing an ambitious agenda to tackle complex neurological disorders that currently lack effective treatments.
Segments
Voyager Therapeutics is deeply entrenched in the biotechnology and gene therapy segments. Its research and development endeavors are squarely aimed at neurological disorders such as:
- Parkinsons Disease: A progressive neurodegenerative disorder characterized by motor and non-motor symptoms that arise from the loss of dopamine-producing neurons in the brain.
- Huntingtons Disease: A hereditary disorder caused by a genetic mutation leading to the degeneration of nerve cells in the brain, resulting in cognitive decline, psychiatric issues, and movement disorders.
- Friedreich’s Ataxia: A rare genetic condition that impacts the nervous system and the heart, leading to progressive loss of coordination and muscle strength due to frataxin protein deficiency.
Products and Services
1. VY-AADC: Voyager’s flagship product candidate, VY-AADC (Aromatic L-Amino Acid Decarboxylase gene therapy), is designed to treat Parkinsons disease by delivering the gene responsible for producing the Aromatic L-Amino Acid Decarboxylase enzyme directly into the brain. This treatment aims to reinstate dopamine levels in patients, potentially alleviating symptoms for an extended duration and improving overall quality of life.
2. VY-HTT01: This investigational gene therapy is developed for the treatment of Huntingtons disease. Its mechanism involves the targeted reduction of the mutant huntingtin protein, which is responsible for the neurodegenerative processes characteristic of the disease. By aiming to reduce the levels of this pathogenic protein, VY-HTT01 seeks to slow disease progression and preserve neurological function in affected individuals.
3. VY-FXN01: An investigational therapy for Friedreichs ataxia, VY-FXN01 aims to enhance the production of frataxin, a protein essential for proper mitochondrial function. Patients with Friedreich’s ataxia suffer from inadequate frataxin levels leading to mitochondrial dysfunction. By restoring frataxin levels, VY-FXN01 holds the potential to slow or even halt the neurological decline associated with this rare inherited disorder.
Proprietary Platforms and Collaborations
- TRACER™ Platform: Voyager Therapeutics employs its proprietary gene therapy platform known as TRACER™ (Translationally-optimized, AAV-based approach to gene therapy). This innovative platform is designed to facilitate the efficient delivery of therapeutic genes to targeted cells within the central nervous system, enhancing the durability and efficacy of their gene therapies. The TRACER™ system allows for precise targeting of neuronal populations, which is crucial for treating complex neurological conditions.
- Collaborative Partnerships: Voyager actively collaborates with leading academic institutions and prominent pharmaceutical companies to accelerate the development and commercialization of its gene therapies. Key partnerships include collaborations with organizations such as Neurocrine Biosciences, AbbVie, and Alpine Immune Sciences. These collaborations aim to leverage combined expertise in advancing new therapies and exploring innovative approaches to treat severe neurological disorders.
Commitment to Patients
Voyager Therapeutics is steadfast in its mission to explore the full potential of gene therapy, focusing on delivering high-impact treatments for unmet medical needs in the realm of severe neurological diseases. The company is dedicated not only to creating transformative therapeutic options but also to improving patients quality of life through effective long-term solutions. By pushing the boundaries of current scientific understanding and technological capabilities, Voyager Therapeutics continues to make significant strides toward addressing the challenges faced by individuals suffering from debilitating neurological disorders.
Segments
Voyager Therapeutics is deeply entrenched in the biotechnology and gene therapy segments. Its research and development endeavors are squarely aimed at neurological disorders such as:
- Parkinsons Disease: A progressive neurodegenerative disorder characterized by motor and non-motor symptoms that arise from the loss of dopamine-producing neurons in the brain.
- Huntingtons Disease: A hereditary disorder caused by a genetic mutation leading to the degeneration of nerve cells in the brain, resulting in cognitive decline, psychiatric issues, and movement disorders.
- Friedreich’s Ataxia: A rare genetic condition that impacts the nervous system and the heart, leading to progressive loss of coordination and muscle strength due to frataxin protein deficiency.
Products and Services
1. VY-AADC: Voyager’s flagship product candidate, VY-AADC (Aromatic L-Amino Acid Decarboxylase gene therapy), is designed to treat Parkinsons disease by delivering the gene responsible for producing the Aromatic L-Amino Acid Decarboxylase enzyme directly into the brain. This treatment aims to reinstate dopamine levels in patients, potentially alleviating symptoms for an extended duration and improving overall quality of life.
2. VY-HTT01: This investigational gene therapy is developed for the treatment of Huntingtons disease. Its mechanism involves the targeted reduction of the mutant huntingtin protein, which is responsible for the neurodegenerative processes characteristic of the disease. By aiming to reduce the levels of this pathogenic protein, VY-HTT01 seeks to slow disease progression and preserve neurological function in affected individuals.
3. VY-FXN01: An investigational therapy for Friedreichs ataxia, VY-FXN01 aims to enhance the production of frataxin, a protein essential for proper mitochondrial function. Patients with Friedreich’s ataxia suffer from inadequate frataxin levels leading to mitochondrial dysfunction. By restoring frataxin levels, VY-FXN01 holds the potential to slow or even halt the neurological decline associated with this rare inherited disorder.
Proprietary Platforms and Collaborations
- TRACER™ Platform: Voyager Therapeutics employs its proprietary gene therapy platform known as TRACER™ (Translationally-optimized, AAV-based approach to gene therapy). This innovative platform is designed to facilitate the efficient delivery of therapeutic genes to targeted cells within the central nervous system, enhancing the durability and efficacy of their gene therapies. The TRACER™ system allows for precise targeting of neuronal populations, which is crucial for treating complex neurological conditions.
- Collaborative Partnerships: Voyager actively collaborates with leading academic institutions and prominent pharmaceutical companies to accelerate the development and commercialization of its gene therapies. Key partnerships include collaborations with organizations such as Neurocrine Biosciences, AbbVie, and Alpine Immune Sciences. These collaborations aim to leverage combined expertise in advancing new therapies and exploring innovative approaches to treat severe neurological disorders.
Commitment to Patients
Voyager Therapeutics is steadfast in its mission to explore the full potential of gene therapy, focusing on delivering high-impact treatments for unmet medical needs in the realm of severe neurological diseases. The company is dedicated not only to creating transformative therapeutic options but also to improving patients quality of life through effective long-term solutions. By pushing the boundaries of current scientific understanding and technological capabilities, Voyager Therapeutics continues to make significant strides toward addressing the challenges faced by individuals suffering from debilitating neurological disorders.